Earnings Scheduled For November 22, 2021
Companies Reporting Before The Bell
• Cerence (NASDAQ:CRNC) is estimated to report quarterly earnings at $0.56 per share on revenue of $97.92 million.
The Week Ahead In Biotech (Nov. 21-Nov. 27): Takeda, Aadi, Fennec FDA Decisions, Earnings In The Spotlight In Holiday-Shortened Week
Biotech stocks showed a lack of direction in the week ending Nov. 19 before finishing modestly higher. Stocks did not have much meaningful catalysts to react to amid the winding down of the reporting season and ahead of the holiday week.
Arrowhead Presents New Clinical Data On ARO-APOC3 At AHA 2021
Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) today announced additional Phase 1/2 clinical data on ARO-APOC3, the company's investigational RNA interference (RNAi) therapeutic targeting apolipoprotein C-III (APOC3)
Arrowhead Pharmaceuticals Announced it Filed for Regulatory Clearance to Begin Phase 1/2a Study of ARO-C3 for Treatment of Complement Mediated Diseases Business Wire – Oct 25 07:30 EDT
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has filed an application for clearance to begin a Phase 1/2a clinical trial of ARO-C3, the company's investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with various complement mediated diseases.
ARWR: New Program Targeting Complement C3 Highlights Expanding Pipeline…
By David Bautz, PhD
NASDAQ:ARWR
READ THE FULL ARWR RESEARCH REPORT
HC Wainwright & Co. Maintains Buy on Arrowhead Pharmaceuticals, Raises Price Target to $100
HC Wainwright & Co. analyst Patrick Trucchio maintains Arrowhead Pharmaceuticals (NASDAQ:ARWR) with a Buy and raises the price target from $95 to $100.
Chardan Capital Maintains Buy on Arrowhead Pharmaceuticals, Lowers Price Target to $94
Chardan Capital analyst Keay Nakae maintains Arrowhead Pharmaceuticals (NASDAQ:ARWR) with a Buy and lowers the price target from $97 to $94.
Recap: Arrowhead Pharmaceuticals Q3 Earnings
Shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) were flat in after-market trading after the company reported Q3 results.
Quarterly Results
Earnings per share were down 123.08% year over year to ($0.29), which missed the estimate of ($0.20).
Arrowhead Pharmaceuticals Q3 EPS $(0.29) Misses $(0.20) Estimate, Sales $45.89M Beat $37.52M Estimate
Arrowhead Pharmaceuticals (NASDAQ:ARWR) reported quarterly losses of $(0.29) per share which missed the analyst consensus estimate of $(0.20) by 45 percent. This is a 123.08 percent decrease over losses of $(0.13) per